Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure I: Introduction

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exercise training for cardiovascular prevention in patients with cancer.

European heart journal·2026

Same author

Cardiac Implantable Electronic Devices in Oncology Patients: Challenges and Management.

Journal of cardiovascular electrophysiology·2026

Same author

GLP-1 Receptor Agonists: From Glycaemic Control to Cardio-Reno-Metabolic Disease Modification.

European heart journal. Quality of care & clinical outcomes·2026

Same author

Ferroptosis-Associated Fibroblast Activation and Transcriptional Remodelling in Human Heart Failure: A Proof-of-Concept Study.

European journal of clinical investigation·2026

Same author

Evaluation and management of recent onset cardiomyopathy in the current era of heart failure therapeutics: a clinical consensus statement of the Heart Failure Association of the ESC.

ESC heart failure·2026

Same author

Hybrid Technique for a Rare Complication of Cardiac Devices Implantation.

Pacing and clinical electrophysiology : PACE·2026

Search research articles

Related Experiment Video

Updated: Feb 20, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Hypothalamic dysfunction in heart failure: pathogenetic mechanisms and therapeutic implications.

Antonios Rigas¹, Dimitrios Farmakis², Georgios Papingiotis¹

¹Heart Failure Unit, Department of Cardiology, Athens University Hospital "Attikon", National and Kapodistrian University of Athens, Athens, Greece.

Heart Failure Reviews

|October 21, 2017

Summary

Heart failure involves neurohumoral activation, with the hypothalamus playing a key role in its mechanisms and comorbidities like depression. This review explores hypothalamic pathways and therapeutic strategies for heart failure.

Keywords:

Depression Heart failure Hypothalamus Hypothalamus-pituitary axis Inflammation Neurohormonal activation

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Related Experiment Videos

Last Updated: Feb 20, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Area of Science:

Neuroscience
Cardiology
Molecular Biology

Background:

Neurohumoral activation is a key feature of heart failure.
The hypothalamus is increasingly recognized for its role in heart failure pathophysiology and comorbidities.
Advances in molecular biology and imaging have improved understanding of hypothalamic function.

Purpose of the Study:

To review neural reflexes and molecular signaling in the hypothalamus related to heart failure.
To examine dysfunctional mechanisms within the hypothalamus in heart failure.
To discuss potential therapeutic implications for heart failure management.

Main Methods:

Literature review of studies on hypothalamic function in heart failure.
Analysis of molecular signaling pathways and neural reflexes.
Examination of imaging and molecular biology findings.

Main Results:

The hypothalamus modulates dysfunctional mechanisms in heart failure.
Hypothalamic dysfunction is linked to comorbidities such as depression in heart failure patients.
Specific neural reflexes and molecular pathways within the hypothalamus are implicated.

Conclusions:

The hypothalamus is central to heart failure pathophysiology and associated comorbidities.
Understanding hypothalamic mechanisms offers new therapeutic avenues for heart failure.
Targeting hypothalamic pathways may improve treatment outcomes for heart failure patients.